secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001703057-23-000038
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q3 revenue plunges to $6.6M from $101M; net loss $0.10/sh vs prior year profit
--------------------------------------------------------------------------------

- Total revenue $6.6M, down 93.5% from $101.4M in Q3 2022.
- Net loss of $28.6M ($0.10 loss per share) vs net earnings of $26.6M ($0.09 EPS) in Q3 2022.
- Cumulative partnered program starts reached 110, up 20% YoY; 10 molecules in clinic.
- Two AbCellera-led programs advanced into IND-enabling studies.
- Cash, cash equivalents, and marketable securities $813.0M; R&D expenses $37.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305723000038/0001703057-23-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305723000038/abcl-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001703057-23-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer